Critically ill participants in the PURIFY-OBS-1 study developed high serum and mucosal antibodies to SARS-CoV-2 spike and N proteins, with particularly higher mucosal IgG IgA and SIgA levels compared to levels in saliva from nonsevere COVID-19 subjects [24]. This evidence concerns the gene CD79A and COVID-19.